The Norwegians followed up their 4-2 win over Israel in Hungary in March with a 5-0 thrashing of Moldova in Chisinau to put Ståle Solbakken's team in pole position in the standings ahead of today ...

Iran is talking tough on the details of a possible nuclear deal with the United States — which just means Team Trump has to get tougher.

Tempus completed confirmatory testing in Verastem’s Phase 2 RAMP-201 clinical trial, which evaluated the combination of avutometinib and defactinib to treat recurrent low-grade serous ovarian ...

The treatment, called avutometinib plus defactinib (Avmapki Fakzynja Co-pack), was developed to treat low-grade serous ovarian cancer (LGSOC). The phase 2 clinical trial that resulted in the approval ...

The FDA has granted accelerated approval to Verastem Oncology’s Avmapki Fakzynja Co-Pack (avutometinib capsules and defactinib tablets). The regulatory action marks the first treatment approved for ...

Verastem Gets FDA Approval of AVMAPKI/FAKZYNJA Combination for Adult Patients With KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer Published: May 8, 2025 at 1:39 p.m. ET Share ...

"Today’s approval of AVMAPKI FAKZYNJA CO-PACK for patients with KRAS-mutated recurrent low-grade serous ovarian cancer represents not only the first-ever FDA-approved treatment specifically for ...

The FDA approved Avmapki Fakzynja Co-pack for KRAS-mutated, recurrent, low-grade serous ovarian cancer after prior systemic therapy. The RAMP-201 trial showed a 44% response rate, with response ...

Low-grade serous ovarian cancer is highly recurrent and less sensitive to chemotherapy compared with high-grade serous ovarian cancer and approximately 6,000 to 8,000 women in the United States — as ...

GREEN BAY, Wis. – The Green Bay Packers and Houston Texans are two of the best teams in the NFL. Jordan Love is one of the top quarterbacks and the Texans have one of the elite pass defenses.

Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 cancer. Most uterine cancers have excellent five-year survival rates – up to 95% for localized ...

Low-grade serous ovarian cancer (LGSOC) patient impact survey research findings. Verastem. March 18, 2024. Accessed September 27, 2024.